Gland Pharma Limited
NSE:GLAND.NS
1777.6 (INR) • At close November 8, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Omzet
| 56,647.22 | 36,246.01 | 43,841.45 | 34,236.37 | 25,717.8 | 19,931.47 | 15,800.65 | 14,791.76 |
| Kosten van de omzet
| 40,045.38 | 16,854.27 | 21,092.17 | 14,918.74 | 11,020.23 | 8,570.21 | 6,607.54 | 5,824.75 |
| Brutowinst
| 16,601.84 | 19,391.74 | 22,749.28 | 19,317.63 | 14,697.57 | 11,361.26 | 9,193.11 | 8,967.01 |
| Brutowinstmarge
| 0.293 | 0.535 | 0.519 | 0.564 | 0.571 | 0.57 | 0.582 | 0.606 |
| Onderzoek- en ontwikkelingskosten
| 1,773 | 403.77 | 426.56 | 321.99 | 228.75 | 207.17 | 189.12 | 507.55 |
| Algemene en administratieve kosten
| 1,324.43 | 485.32 | 313.62 | 162.7 | 139.51 | 88.63 | 503.72 | 0 |
| Verkoop- en marketingkosten
| 374.64 | 270.32 | 409.81 | 366.94 | 170.76 | 138.78 | 99.31 | 0 |
| Verkoop-, algemene en administratieve kosten
| 4,943.77 | 755.64 | 723.43 | 529.64 | 310.27 | 227.41 | 603.03 | 1,607.84 |
| Overige kosten
| 1,702.35 | 2,404.63 | 15.99 | 82.77 | 9.78 | 5.76 | 2.82 | 0 |
| Bedrijfskosten
| 6,716.77 | 10,611.47 | 8,745.52 | 7,280.42 | 6,072.61 | 5,222.71 | 4,611.11 | 3,315.14 |
| Bedrijfsresultaat
| 9,885.07 | 8,844.4 | 14,000.34 | 12,034.45 | 8,608.8 | 6,243.83 | 4,582 | 5,578.72 |
| Bedrijfsresultaat ratio
| 0.175 | 0.244 | 0.319 | 0.352 | 0.335 | 0.313 | 0.29 | 0.377 |
| Totaal overige inkomsten en kosten netto
| 1,440.35 | 1,701.42 | 2,185.18 | 1,313.65 | 1,319.86 | 618.95 | 432.65 | 201.39 |
| Inkomen voor belasting
| 11,325.42 | 10,545.82 | 16,185.52 | 13,348.1 | 9,928.66 | 6,862.78 | 5,014.65 | 5,780.11 |
| Inkomen voor belasting ratio
| 0.2 | 0.291 | 0.369 | 0.39 | 0.386 | 0.344 | 0.317 | 0.391 |
| Belastingkosten
| 3,600.82 | 2,735.39 | 4,068.88 | 3,378.47 | 2,200.08 | 2,344.22 | 1,804.14 | 1,642.85 |
| Nettowinst
| 7,724.6 | 7,810.43 | 12,116.64 | 9,969.63 | 7,728.58 | 4,518.56 | 3,210.51 | 4,137.26 |
| Nettowinstmarge
| 0.136 | 0.215 | 0.276 | 0.291 | 0.301 | 0.227 | 0.203 | 0.28 |
| WPA (Winst Per Aandeel)
| 46.9 | 47.44 | 73.81 | 63.07 | 49.88 | 27.67 | 19.66 | 26.7 |
| Verwaterde WPA
| 46.89 | 47.43 | 73.64 | 62.99 | 49.88 | 27.67 | 19.66 | 26.7 |
| EBITDA
| 13,330.73 | 12,652.26 | 17,282.81 | 14,367.53 | 10,779.27 | 7,804.02 | 5,843.42 | 6,320.19 |
| EBITDA ratio
| 0.235 | 0.349 | 0.394 | 0.42 | 0.419 | 0.392 | 0.37 | 0.427 |